Swiss National Bank Has $10.28 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Swiss National Bank lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 0.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 256,600 shares of the company’s stock after selling 1,400 shares during the period. Swiss National Bank owned approximately 0.18% of Ionis Pharmaceuticals worth $10,279,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in Ionis Pharmaceuticals in the first quarter worth approximately $255,000. CANADA LIFE ASSURANCE Co grew its position in Ionis Pharmaceuticals by 2.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 41,880 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,099 shares during the period. Advisors Asset Management Inc. increased its stake in Ionis Pharmaceuticals by 948.8% during the 1st quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company’s stock valued at $138,000 after purchasing an additional 2,875 shares in the last quarter. Paloma Partners Management Co bought a new stake in Ionis Pharmaceuticals during the 1st quarter valued at $213,000. Finally, Kennedy Capital Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 9.2% in the first quarter. Kennedy Capital Management LLC now owns 249,527 shares of the company’s stock valued at $10,817,000 after buying an additional 21,102 shares in the last quarter. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ IONS opened at $34.01 on Monday. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The stock has a market capitalization of $5.37 billion, a PE ratio of -13.94 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a one year low of $33.33 and a one year high of $54.44. The business’s fifty day moving average price is $38.70 and its 200-day moving average price is $42.49.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the sale, the chief executive officer now owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Eric Swayze sold 1,194 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the transaction, the executive vice president now directly owns 33,713 shares of the company’s stock, valued at $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,197 shares of company stock valued at $315,310 over the last three months. 2.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Guggenheim decreased their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Wells Fargo & Company dropped their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Finally, Piper Sandler reduced their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.